Tempus AI is set to release its Q1 2025 earnings, with forecasts indicating a revenue of $248.1 million and a GAAP EPS loss of $(0.27). Founded by Eric Lefkofsky, Tempus serves as an integral platform in oncology and life sciences, utilizing AI and proprietary datasets for clinical decision-making and pharmaceutical applications. Investors are particularly interested in the company's performance across its commercial segments, guidance updates, and international expansion efforts in the EU, as it aims for $1.24 billion in revenue for the year, reflecting nearly 78% growth.
Tempus AI, a leader in clinical AI and health data infrastructure, is poised for significant growth with a projected revenue of $1.24 billion in 2025.
Investors are focused on Tempusâ core segments: clinical testing, pharma SaaS, and data licensing, alongside guidance on international partnerships and enterprise renewals.
Collection
[
|
...
]